Research programme: antisense oligonucleotides - Evotec/Secarna Therapeutics
Latest Information Update: 30 Jul 2024
At a glance
- Originator Evotec SE; Secarna Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
Most Recent Events
- 30 Jul 2024 Preclinical trials in Neurodegenerative disorders in Germany (Parenteral), prior to July 2024 (Secarna Pharmaceuticals pipeline, July 2024)
- 28 Mar 2024 Bristol Myers Squibb enters into an exclusive global license agreement with Evotec SE for selected late-stage neurodegeneration discovery programmes that were developed and progressed within the collaboration
- 05 Aug 2020 Evotec SE and Secarna Pharmaceuticals agree to co-develop antisense oligonucleotides